AcuityBio, Inc.

We have developed a bio-compatible, biodegradable, drug-eluting surgical implant that prevents post-surgical lung cancer recurrence

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Newton, MA, USA
  • Currency USD
  • Founded April 2010
  • Employees 4
  • Incorporation Type C-corp
  • Website acuitybio.com

Company Summary

Prevention of cancer recurrence is a large clinical unmet need. Localized drug delivery with our product ABC103 prevents cancer recurrence. ABC103 will increase survival, provide a better quality of life to patients without changes to standard of care procedures, devices using approved drugs within existing medical reimbursement. Our market $1.2B, non-small cell lung cancer 60K patients/yr in US 180K patients per year in EU and Asia

Team

  • John J. Schwartz
    President annd CEO

    Dr. Schwartz has been a successful academic, consultant, entrepreneur and angel investor. He is presently President and CEO of AcuityBio, Inc. AcuityBio is a preclinical company commercializing novel surgical implant, drug delivery technology developed at Boston University and Harvard Medical School. AcuityBio's first product candidate, ABC-100, prevents post-surgical lung cancer recurrence. Jay, was venture backed co-founder of Adnexus

  • Aaron Colby
    Senior Scientist

    MS, PhD Biomedical Engineering, Boston University, experience in polymer films and nanoparticle drug delivery for lung cancer

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free